{"id":"https://openalex.org/W2098089006","doi":"https://doi.org/10.1128/aac.01391-06","title":"Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers","display_name":"Safety and Pharmacokinetics of Bevirimat (PA-457), a Novel Inhibitor of Human Immunodeficiency Virus Maturation, in Healthy Volunteers","publication_year":2007,"publication_date":"2007-06-19","ids":{"openalex":"https://openalex.org/W2098089006","doi":"https://doi.org/10.1128/aac.01391-06","mag":"2098089006","pmid":"https://pubmed.ncbi.nlm.nih.gov/17576843","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/2043192"},"language":"en","primary_location":{"id":"doi:10.1128/aac.01391-06","doi":"https://doi.org/10.1128/aac.01391-06","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.01391-06","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2043192","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088174722","display_name":"David E. Martin","orcid":"https://orcid.org/0000-0003-2820-5983","observed_orcids":["https://orcid.org/0000-0003-2820-5983"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"David E. Martin","raw_affiliation_strings":["Panacos Pharmaceuticals, Inc., Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Panacos Pharmaceuticals, Inc., Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111914294","display_name":"Robert A. Blum","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Blum","raw_affiliation_strings":["Buffalo Clinical Research Center, Buffalo, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Buffalo Clinical Research Center, Buffalo, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038285212","display_name":"John H. Wilton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"John Wilton","raw_affiliation_strings":["Emprexe Analytical LLC, Buffalo, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Emprexe Analytical LLC, Buffalo, New York","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004377402","display_name":"Judy Doto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Judy Doto","raw_affiliation_strings":["Panacos Pharmaceuticals, Inc., Gaithersburg, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Panacos Pharmaceuticals, Inc., Gaithersburg, Maryland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060179371","display_name":"Hal Galbraith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hal Galbraith","raw_affiliation_strings":["Quintiles, Inc., Kansas City, Missouri"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quintiles, Inc., Kansas City, Missouri","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009828058","display_name":"Gina L. Burgess","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108991","display_name":"IQVIA (United States)","ror":"https://ror.org/01mk44223","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108991"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gina L. Burgess","raw_affiliation_strings":["Quintiles, Inc., Kansas City, Missouri"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Quintiles, Inc., Kansas City, Missouri","institution_ids":["https://openalex.org/I4210108991"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059292691","display_name":"Philip C. Smith","orcid":"https://orcid.org/0000-0003-2102-1209","observed_orcids":["https://orcid.org/0000-0003-2102-1209"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Philip C. Smith","raw_affiliation_strings":["University of North Carolina, Chapel Hill, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, Chapel Hill, North Carolina","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091763566","display_name":"Charles H. Ballow","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Charles Ballow","raw_affiliation_strings":["Buffalo Clinical Research Center, Buffalo, New York"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Buffalo Clinical Research Center, Buffalo, New York","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5088174722"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":5.3804,"has_fulltext":true,"cited_by_count":76,"citation_normalized_percentile":{"value":0.9602815,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"51","issue":"9","first_page":"3063","last_page":"3066"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevirimat","display_name":"bevirimat","score":0.996999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8619999885559082},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.8050000071525574},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.6620000004768372},{"id":"https://openalex.org/keywords/dose-proportionality","display_name":"dose proportionality","score":0.8339999914169312},{"id":"https://openalex.org/keywords/plasma-half-life","display_name":"plasma half-life","score":0.652999997138977},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.8700000047683716},{"id":"https://openalex.org/keywords/hiv-treatment","display_name":"HIV treatment","score":0.7519999742507935}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.9531607627868652},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8347994685173035},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6334237456321716},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6068602800369263},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.6045544147491455},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5228579044342041},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.5181587934494019},{"id":"https://openalex.org/C3941253","wikidata":"https://www.wikidata.org/wiki/Q47270","display_name":"Half-life","level":3,"score":0.4778304100036621},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.47581011056900024},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.24645453691482544},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.05949479341506958},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013386","descriptor_name":"Succinates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013386","descriptor_name":"Succinates","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D013386","descriptor_name":"Succinates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014315","descriptor_name":"Triterpenes","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014315","descriptor_name":"Triterpenes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014315","descriptor_name":"Triterpenes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053978","descriptor_name":"Pentacyclic Triterpenes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1128/aac.01391-06","doi":"https://doi.org/10.1128/aac.01391-06","is_oa":false,"landing_page_url":"https://doi.org/10.1128/aac.01391-06","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:2043192","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2043192","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:17576843","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17576843","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"},{"id":"pmh:cdr.lib.unc.edu:hm50tz430","doi":null,"is_oa":true,"landing_page_url":"https://doi.org/10.17615/hmy5-2264","pdf_url":"https://doi.org/10.17615/hmy5-2264","source":{"id":"https://openalex.org/S4306401075","display_name":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I114027177","host_organization_name":"University of North Carolina at Chapel Hill","host_organization_lineage":["https://openalex.org/I114027177"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Antimicrobial Agents and Chemotherapy, 51(9)","raw_type":"Article"},{"id":"doi:10.17615/hmy5-2264","doi":"https://doi.org/10.17615/hmy5-2264","is_oa":true,"landing_page_url":"https://doi.org/10.17615/hmy5-2264","pdf_url":null,"source":{"id":"https://openalex.org/S7407051488","display_name":"UNC Libraries","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"pmh:oai:pubmedcentral.nih.gov:2043192","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/2043192","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2098089006.pdf","grobid_xml":"https://content.openalex.org/works/W2098089006.grobid-xml"},"referenced_works_count":9,"referenced_works":["https://openalex.org/W1999842374","https://openalex.org/W2003199949","https://openalex.org/W2050485392","https://openalex.org/W2050621055","https://openalex.org/W2132762790","https://openalex.org/W2146786722","https://openalex.org/W2318289184","https://openalex.org/W2405656175","https://openalex.org/W4233840672"],"related_works":["https://openalex.org/W1977687204","https://openalex.org/W2158408725","https://openalex.org/W1588114215","https://openalex.org/W1986659065","https://openalex.org/W1983701213","https://openalex.org/W1457137500","https://openalex.org/W2429604444","https://openalex.org/W3091031513","https://openalex.org/W1966015585","https://openalex.org/W7112058573"],"abstract_inverted_index":{"Bevirimat":[0],"(BVM;":[1],"formerly":[2],"known":[3],"as":[4],"PA-457)":[5],"is":[6,17],"a":[7,38,185],"novel":[8],"inhibitor":[9],"of":[10,23,28,50,58,81,107,110,144,161,196,202],"human":[11],"immunodeficiency":[12],"virus":[13],"(HIV)":[14],"maturation":[15],"that":[16,181,182],"being":[18,124],"developed":[19],"for":[20,105],"the":[21,44,77,82,108,145,149,152,193],"treatment":[22],"HIV":[24],"infection.":[25],"The":[26,132,139,199],"pharmacokinetics":[27,78,191],"this":[29],"agent":[30],"in":[31,37,42],"healthy":[32],"male":[33],"volunteers":[34],"were":[35,163,167,176],"studied":[36],"randomized,":[39],"double-blind":[40],"study":[41],"which":[43],"participants":[45],"received":[46],"single":[47,197],"oral":[48,118,159,194],"doses":[49,57,160],"placebo":[51],"(n":[52,67],"=":[53,68],"8)":[54],"or":[55,64],"escalating":[56],"BVM":[59,113,162,183,203],"at":[60],"25,":[61],"50,":[62],"100,":[63],"250":[65],"mg":[66],"6":[69],"per":[70],"dose);":[71],"escalation":[72],"was":[73,89,98,114,134,155],"performed":[74],"only":[75],"after":[76,94,103,117,130],"and":[79,96,148,171],"safety":[80],"preceding":[83],"dose":[84,156],"had":[85],"been":[86],"evaluated.":[87],"Plasma":[88],"collected":[90,99],"over":[91,100],"480":[92],"h":[93,102,129],"dosing":[95,104],"urine":[97],"48":[101],"determination":[106,143],"values":[109],"pharmacokinetic":[111,187],"parameters.":[112],"well":[115,164],"absorbed":[116],"administration,":[119],"with":[120,189],"peak":[121,146],"plasma":[122],"concentrations":[123],"achieved":[125],"1":[126],"to":[127,136],"3":[128],"dosing.":[131,207],"half-life":[133,201],"60":[135],"80":[137],"h.":[138],"exposure":[140],"assessed":[141],"by":[142],"concentration":[147],"area":[150],"under":[151],"concentration-time":[153],"curve":[154],"proportional.":[157],"Single":[158],"tolerated:":[165],"there":[166],"no":[168,172],"dose-limiting":[169],"toxicities,":[170],"serious":[173],"adverse":[174],"events":[175],"reported.":[177],"These":[178],"findings":[179],"suggest":[180],"offers":[184],"favorable":[186],"profile,":[188],"predictable":[190],"following":[192],"administration":[195],"doses.":[198],"long":[200],"may":[204],"facilitate":[205],"once-daily":[206]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}